Supernus Pharmaceuticals (SUPN) has released an update.
Supernus Pharmaceuticals triumphed in a patent infringement lawsuit against Torrent Pharmaceuticals and its subsidiary, with a New Jersey District Court ruling that Torrent’s attempt to market a generic version of Trokendi XR® violated Supernus’ patents. This victory safeguards Supernus’ exclusive rights, ensuring their branded product remains protected from generic competition prior to patent expiration.
For further insights into SUPN stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
